布地格福(Budesonide/Formoterol fumarate/Glycopyrronium Bromide) - 药物靶点：GR x mAChRs x β2-adrenergic receptor_在研适应症：慢性支气管炎，慢性阻塞性肺疾病，肺气肿_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BGF MDI、Breztri Aerosphere、Budesonide/Glycopyrronium Bromide/Formoterol Fumarate

+ [17]

靶点

GR x mAChRs x β2-adrenergic receptor

作用方式

激动剂、拮抗剂

作用机制

GR激动剂(糖皮质激素受体激动剂)、mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

感染呼吸系统疾病免疫系统疾病

在研适应症

慢性支气管炎慢性阻塞性肺疾病肺气肿+ [4]

非在研适应症

闭塞性细支气管炎

原研机构

AstraZeneca PLC

在研机构

阿斯利康投资（中国）有限公司AstraZeneca Dunkerque Production SCS

AstraZeneca PLC

+ [4]

非在研机构-

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (2019-06-18),

慢性支气管炎慢性阻塞性肺疾病肺气肿

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C23H28N2O8

InChIKeyZDUPYZMAPCZGJO-DZTPFQSQSA-N

CAS号43229-80-7

查看全部结构式(3)

关联

53

项与布地格福相关的临床试验

NCT06531798

/ Not yet recruiting临床4期

Post-marketing Phase IV, Multicenter, Prospective Study to Observe the Safety and Tolerability of Breztri aerosphereTM Containing a Fixed Dose Combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol Fumarate Dehydrate 5 mcg in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.

开始日期2025-05-01

申办/合作机构

AstraZeneca PLC

NCT06905483

/ Recruiting临床4期IIT

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

The goal of this clinical trial is to determine if triple inhaled therapy with Budesonide/Glycopyrronium/Formoterol (BGF) and Fluticasone Furoate/Umeclidinium/Vilanterol (FUV) are effective in treating patients with stable chronic obstructive pulmonary disease (COPD). It will also assess the safety of both drugs.
The main questions it aims to answer are:
* Does BGF demonstrate a comparable effect to FUV in COPD participants?
* What medical problems do participants experience when taking BGFand FUV?

开始日期2025-04-01

申办/合作机构

Thammasat University

NCT06844175

/ Not yet recruitingN/AIIT

A Prospective, Multicenter Cohort Study of Multidimensional Screening and Triple Drug Intervention in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-chronic Obstructive Pulmonary Disease

At present, patients with early COPD and pre-COPD have not been paid attention to in clinical work. This study aims to actively screen such patients in high-risk groups to clarify their prevalence, monitor and analyze relevant clinical and biological indicators, and find sensitive indicators to assist in early diagnosis. Based on the updated definition of COPD in GOLD2022, we pay attention to the concept of early COPD and pre-COPD. After the completion of patient enrollment and data collection, we will further explore the effect of triple inhaled drug intervention on the development of lung function in patients with early COPD and pre-COPD, so as to provide clinical support for early screening and early treatment of COPD.
1. Patients with early COPD and pre-COPD were selected from 20 hospitals in 17 cities of Shandong province to understand the prevalence and basic characteristics of such diseases in the province, and then were divided into groups and treated.
2. The specificity and sensitivity of pulmonary function parameters (FEV1%,FEV1/FVC, DLco, etc.) and imaging parameters (MLD, Perc15, %LAA-950HU, etc.) alone or in combination in the diagnosis of early COPD and pre-COPD, and the predictive diagnostic model/system was established.
3. Treatment of early COPD and pre-COPD: eligible patients were given triple inhalation therapy or placebo, and the effects of triple inhalation therapy or not on clinical symptoms, pulmonary function, and imaging parameters were compared.
This study aims to determine the prevalence of early COPD in Shandong province and provide a reference for the treatment of this population.

开始日期2025-03-01

申办/合作机构

山东省千佛山医院

100 项与布地格福相关的临床结果

登录后查看更多信息

100 项与布地格福相关的转化医学

登录后查看更多信息

100 项与布地格福相关的专利（医药）

登录后查看更多信息

71

项与布地格福相关的文献（医药）

2025-04-17·Advanced biology

Novel Biologically Active Glass Fiber Functionalized Using Magnesium Phosphate Cement Promotes Bone and Vascular Regeneration.

Article

作者: Lu, Yuzheng ; Peng, Jiang ; Wu, Yanbin ; Zhang, Yao ; Meng, Haoye ; Lu, Qiang ; Ye, Jianting ; Ding, Lixiang ; Xiong, Yingjie ; Xu, Wenjing ; Shan, Yanbo ; Song, Jipeng ; Lin, Wancheng

Magnesium phosphate cement (MPC) continues to gain attention in the field of biomedicine. However, its suboptimal mechanical strength and weak biological activity hinder its wider clinical application. Given the excellent biological characteristics of bioglass fiber (BGF), In this study, magnesium phosphate bone cement (BMPC) containing MPC and BGF with different concentrations (0%, 10%, 20%) are fabricated. Called (MPC, 10BMPC, 20BMPC) respectively. BGF-induced mechanical strengthening is verified through physical and chemical performance tests. In vitro experiments showed that BMPC have better osteogenic properties than MPC and can enhance the proliferation and adhesion capacity of human umbilical vein endothelial cells. In vivo experiment, 20BMPC can significantly promote bone regeneration and vascular network formation, and histological analysis further confirmed the osteogenic capacity of 20BMPC. Transcriptomic analyses confirmed that the activities of the Notch pathway and Hif1 pathway are upregulated in the 20BMPC group, reflecting the strong interconnection between osteogenesis and angiogenesis. 20BMPC, which have the highest BGF content, showed the best performance among all the tested materials. This study showed that BGF improved the mechanical strength of bone cement and enhanced its osteogenic and angiogenic abilities. Therefore, 20BMPC can be used as a new bone repair material.

2025-04-01·The American Journal of Medicine

Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study

Article

作者: Hawkins, Nathaniel M ; Vogelmeier, Claus F. ; Müllerová, Hana ; Vogelmeier, Claus F ; Rhodes, Kirsty ; Pollack, Michael ; Hawkins, Nathaniel M. ; Anzueto, Antonio ; Marshall, Jonathan ; Rapsomaniki, Eleni

BACKGROUNDPatients with chronic obstructive pulmonary disease (COPD) have elevated cardiopulmonary and mortality risk, particularly following exacerbations. While single inhaler triple therapies (SITTs), such as budesonide/glycopyrrolate/formoterol fumarate (BGF), reduce cardiopulmonary risk versus dual bronchodilator therapy, there is limited evidence comparing outcomes with SITTs versus multiple inhaler triple therapies (MITTs).METHODSSKOPOS-MAZI was a retrospective comparative effectiveness study in patients with COPD aged ≥40 years using US administrative claims data from Optum's deidentified Clinformatics® Data Mart Database. The primary and secondary endpoints were time to all-cause mortality and time to first severe cardiopulmonary event following initiation of BGF or MITT (identification period: October 1, 2020-June 30, 2023; index date: first prescription fill). Relative hazards of outcomes were assessed until a censoring event using Cox proportional hazards models, with inverse propensity treatment weighting accounting for between-group imbalances (standardized mean difference >0.1) in baseline characteristics.RESULTSIn the primary cohort, risk (hazard ratio [95% confidence intervals]) of all-cause mortality and a first severe cardiopulmonary event were 18% (0.82 [0.75, 0.91]) and 12% (0.88 [0.83, 0.93]) lower in patients initiating BGF versus MITT; results were consistent across censoring definitions, landmark periods, and sensitivity cohorts.CONCLUSIONIn this real-world comparative effectiveness study of patients with COPD initiating BGF or MITT, BGF was associated with lower all-cause mortality and severe cardiopulmonary event risk versus MITT after accounting for between-group differences in baseline sociodemographic and clinical characteristics. This study supports the benefits of BGF over MITT and the need to consider proactive use of SITTs in COPD management.

2025-02-01·American Journal of Respiratory and Critical Care Medicine

Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)

Article

作者: Hurst, John R. ; Arya, Niki ; Patel, Mehul ; Han, MeiLan K. ; Singh, Dave ; Bowen, Karin ; Parikh, Himanshu ; Movitz, Charlotta ; Mushunje, Alec ; Gale, Chris P. ; Martinez, Fernando J. ; Fredriksson, Martin ; Kisielewicz, Dobrawa ; Ojili, Nikki

Rationale: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations and all-cause mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF). However, the effect of BGF on cardiovascular events versus GFF remains unevaluated. Furthermore, the effect of BGF on time to first severe exacerbation has not been reported. Objectives: To assess the effects of BGF 320/18/9.6 μg (BGF 320) and other inhaled corticosteroid-containing arms on cardiovascular and severe cardiopulmonary endpoints versus GFF in patients with COPD from the ETHOS trial. Methods: Patients with moderate to very severe COPD and a history of exacerbations were randomized to twice-daily BGF 320, BGF 160/18/9.6 μg, BFF 320/9.6 μg, or GFF 18/9.6 μg (GFF). Time to first severe COPD exacerbation was a prespecified endpoint; post hoc cardiovascular and severe cardiopulmonary endpoints included time to first major adverse cardiac event, time to first cardiovascular adverse event (AE) of special interest, time to first cardiac AE, and time to the composite endpoint of first severe cardiopulmonary event. Measurements and Main Results: BGF 320 reduced the rate of first occurrence (hazard ratio [95% confidence interval]) of cardiovascular and severe cardiopulmonary events versus GFF, including for time to first cardiovascular adverse event of special interest (0.63 [0.48, 0.82]), cardiac AE (0.60 [0.48, 0.76]), and severe cardiopulmonary event (0.80 [0.67, 0.95]). Conclusions: BGF had a benefit on cardiovascular endpoints and severe cardiopulmonary events versus GFF in patients with moderate to very severe COPD.

90

项与布地格福相关的新闻（医药）

2025-05-03

·药明康德

吸一吸显著缓解哮喘，阿斯利康小分子疗法达所有临床主要终点；双抗疗法组合即将递交监管申请

治疗哮喘，阿斯利康三联疗法达到两项3期临床试验临床主要终点阿斯利康（AstraZeneca）公司日前宣布，该公司开发的三联吸入气雾剂Breztri Aerosphere（布地奈德/格隆溴铵/富马酸福莫特罗），在哮喘控制不佳患者中进行的两项3期临床试验KALOS和LOGOS中获得积极顶线结果。研究显示，该疗法达到所有主要终点，在肺功能方面相较于吸入性糖皮质激素/长效β2受体激动剂（ICS/LABA）双联疗法实现了具有统计学显著性和临床意义的改善。KALOS和LOGOS是两项重复设计的随机、双盲临床试验，旨在评估Breztri作为哮喘潜在治疗选择的疗效和安全性。两项研究比较了Breztri与ICS/LABA维持治疗在成人及青少年哮喘控制不佳患者中的疗效和安全性。两项3期试验的完整结果将提交监管机构，并在即将召开的医学会议中公布。Breztri是一种吸入式三联组合疗法，目前已在包括美国、欧盟、中国和日本在内的全球80多个国家和地区获批用于治疗成人慢性阻塞性肺病（COPD）。CD20/CD3双特异性抗体组合达到3期临床主要终点，即将递交监管申请Genmab公司日前宣布，计划于2025年上半年向美国FDA提交皮下注射epcoritamab的补充生物制品许可申请（sBLA），与利妥昔单抗和来那度胺（R2方案）联用，治疗至少接受过一种系统性治疗后的复发或难治性（R/R）滤泡性淋巴瘤（FL）成人患者。该sBLA的提交决定基于3期临床试验EPCORE FL-1的积极顶线结果。该试验评估了epcoritamab联合R2方案与单用R2方案在R/R FL成人患者中的疗效。根据独立数据监查委员会进行的中期分析，研究达到了总缓解率的主要终点（p值<0.0001）。Epcoritamab联合R2方案在R/R FL成人患者中的安全性特征与epcoritamab和R2各自已知的安全性特征一致，未观察到新的安全信号。完整研究结果预计将于今年晚些时候提交至即将召开的医学会议展示，并与全球监管机构进行沟通。Epcoritamab是一种IgG1型双特异性抗体，由Genmab公司和艾伯维（AbbVie）联合开发，并通过皮下注射方式给药。Genmab的DuoBody-CD3技术旨在将细胞毒性T细胞特异性引导至靶细胞，以激发免疫反应。Epcoritamab可同时结合T细胞表面的CD3和B细胞表面的CD20，进而诱导T细胞介导的CD20阳性细胞杀伤。参考资料：[1] Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL). Retrieved May 2, 2025, from https://www.businesswire.com/news/home/20250501833016/en/Genmab-to-Submit-Supplemental-Biologics-License-Application-sBLA-to-U.S.-Food-and-Drug-Administration-for-Epcoritamab-Plus-Rituximab-and-Lenalidomide-R2-in-Patients-with-RelapsedRefractory-Follicular-Lymphoma-FL[2] BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma. Retrieved May 2, 2025, from https://www.businesswire.com/news/home/20250502498123/en/BREZTRI-met-primary-endpoints-in-KALOS-and-LOGOS-Phase-III-trials-in-asthma免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期引进/卖出临床2期临床结果临床1期

2025-05-03

·医药魔方Info

阿斯利康两项哮喘III期研究成功

5月2日，阿斯利康宣布固定剂量三联组合疗法Breztri Aerosphere（布地奈德+福莫特罗+格隆溴铵）在III期KALOS和LOGOS研究中达到所有主要终点，与吸入性糖皮质激素/长效 β2 受体激动剂（ICS/LABA）药物相比，该三联组合疗法在改善肺功能方面具有统计学意义和临床意义。Breztri包含吸入糖皮质激素布地奈德、长效抗胆碱能药物格隆溴铵、长效β2受体激动剂富马酸福莫特罗三种药物成分。该药已在中国、美国、欧洲和日本获批用于慢性阻塞性肺疾病（COPD）患者的维持治疗。KALOS和LOGOS研究是随机、双盲III期临床研究，旨在评估Breztri作为潜在哮喘治疗方法，对比维持ICS/LABA治疗在成人和青少年未控哮喘患者中的疗效和安全性。安全性方面，KALOS或LOGOS研究中未发现Breztri新的安全性或耐受性信号。两项III期研究的完整结果将在未来的医学会议上公布，并与监管机构共享。哮喘是一种常见的慢性呼吸道疾病，其特征是气道炎症和肌肉紧缩（支气管收缩），可能导致呼吸困难。全球有多达2.62亿人受哮喘影响，估计近一半接受双重疗法的患者仍未得到控制，这会显著限制肺功能并降低生活质量。阿斯利康生物制药研发执行副总裁Sharon Barr表示：“我们对KALOS和 LOGOS研究的结果感到兴奋，这些结果表明Breztri可能有助于改善全球数百万哮喘患者的生活。这些哮喘数据在Breztri于慢性阻塞性肺病（COPD）中的成熟应用基础上更进一步，我们期待与监管机构分享，以将这种重要药物带给更广泛的患者群体。”Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

临床3期临床结果临床成功

2025-05-02

·PMLiVE

AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

AstraZeneca (AZ) has shared positive late-stage results for its inhaled fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) in asthma. The phase 3 KALOS and LOGOS replicate trials have been evaluating the therapy against maintenance treatment with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines in adults and adolescents with uncontrolled cases of the respiratory disease. Breztri Aerosphere demonstrated a statistically significant and clinically meaningful improvement in lung function compared to ICS/LABA medicines, and there were no new safety or tolerability signals identified for Breztri Aerosphere in either study. Up to 262 million people worldwide are affected by asthma, a chronic condition characterised by inflammation and muscle tightening in the airways. Despite the availability of standard-of-care (SOC) medicines, it is estimated that nearly half of patients receiving dual therapy remain uncontrolled and continue to experience frequent wheezing, coughing, breathlessness and chest tightness. “The results from the KALOS and LOGOS trials are exciting and demonstrate the potential of [Breztri Aerosphere] to evolve the SOC to more effectively treat asthma in a single inhaled triple therapy for patients who remain uncontrolled with dual maintenance therapy,” said primary investigator Alberto Papi, University of Ferrara and S. Anna University Hospital. AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory disease that causes progressive lung function decline. Full results from KALOS and LOGOS will be shared with regulatory authorities and presented at an upcoming medical meeting, AZ outlined. Sharon Barr, executive vice president, biopharmaceuticals research and development, AZ, said: “We are excited by the positive results from the KALOS and LOGOS trials, which demonstrate that Breztri could help improve the lives of the millions of patients living with asthma. “This asthma data builds on the well-established profile of Breztri in COPD, and we look forward to sharing with regulatory authorities to bring this important medicine to a wider group of patients.” The announcement comes just days after AZ’s Calquence (acalabrutinib) regimens were recommended by the European Medicines Agency’s human medicines committee to treat chronic lymphocytic leukaemia.

临床3期临床结果上市批准

100 项与布地格福相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	R03AL11	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性支气管炎	日本	AstraZeneca KK	2019-06-18
慢性阻塞性肺疾病	日本	AstraZeneca KK	2019-06-18
肺气肿	日本	AstraZeneca KK	2019-06-18

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
哮喘	临床3期	美国	AstraZeneca PLC	2011-12-01
哮喘	临床3期	阿根廷	AstraZeneca PLC	2011-12-01
哮喘	临床3期	智利	AstraZeneca PLC	2011-12-01
哮喘	临床3期	哥伦比亚	AstraZeneca PLC	2011-12-01
哮喘	临床3期	泰国	AstraZeneca PLC	2011-12-01
哮喘	临床3期	俄罗斯	AstraZeneca PLC	2011-12-01
哮喘	临床3期	南非	AstraZeneca PLC	2011-12-01
哮喘	临床3期	捷克	AstraZeneca PLC	2011-12-01
哮喘	临床3期	波兰	AstraZeneca PLC	2011-12-01
哮喘	临床3期	斯洛伐克	AstraZeneca PLC	2011-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05569421 (CTgov)	临床1期	慢性阻塞性肺疾病	108	BAB+BGF (Treatment A)	醖繭膚積顧鬱遞齋艱鬱(窪繭選襯繭繭築餘蓋鑰) = 鹹選廠鏇鹹積鬱鏇築膚範憲願鹹鏇鏇願積積積 (願壓廠製獵築衊積範鹹, 淵繭醖範構築願糧窪製 ~ 窪範積憲淵鹹顧廠選廠) 更多	-	2025-04-29
				BAB+BGF (Treatment B (Replicate 1))	醖繭膚積顧鬱遞齋艱鬱(窪繭選襯繭繭築餘蓋鑰) = 願餘鹽鑰窪淵築簾鑰膚範憲願鹹鏇鏇願積積積 (願壓廠製獵築衊積範鹹, 鹽窪淵範觸淵襯積齋衊 ~ 繭艱餘衊鹽網獵蓋繭獵) 更多
ATS2024	N/A	慢性阻塞性肺疾病	-	Budesonide/Glycopyrrolate/Formoterol (BGF)	窪願製範製壓範衊願顧(壓範齋製憲鏇齋蓋夢鏇) = 積網憲獵淵製選願衊願觸願顧膚築遞積窪繭獵 (獵衊窪憲糧積網願選餘 )	-	2024-05-19
				Multiple Inhaler Triple Therapy (MITT)	窪願製範製壓範衊願顧(壓範齋製憲鏇齋蓋夢鏇) = 醖膚憲壓願繭網齋遞壓觸願顧膚築遞積窪繭獵 (獵衊窪憲糧積網願選餘 )
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)	構廠糧網廠醖構簾鑰淵(壓鹽觸艱獵構蓋獵獵願) = 觸廠艱蓋鏇簾觸獵衊積鑰膚鬱選鹹膚築顧繭繭 (鹽糧範鏇壓構簾淵觸鹽 )	-	2024-05-19
				Budesonide/Glycopyrrolate/Formoterol Fumarate (BUD/GLY/FORM)	構廠糧網廠醖構簾鑰淵(壓鹽觸艱獵構蓋獵獵願) = 築構範鹽構積選遞膚範鑰膚鬱選鹹膚築顧繭繭 (鹽糧範鏇壓構簾淵觸鹽 )
NCT03836677 (Pubmed \| Respir Res)	临床3期	慢性阻塞性肺疾病	23	Budesonide/glycopyrrolate/formoterol fumarate	(壓範構糧夢網選齋夢鹹): GM = 1.09 (95% CI, 1.03 ~ 1.16)	-	2021-07-01
				Glycopyrrolate/formoterol fumarate
NCT02465567 (ETHOS, CTgov)	临床3期	慢性阻塞性肺疾病	8,588	Budesonide+Glycopyrronium+Formoterol Fumarate (BGF MDI 320/14.4/9.6 μg)	網鏇壓遞製鬱築糧衊夢(餘鏇齋選壓願繭糧齋範) = 醖淵憲壓構窪醖蓋顧獵壓糧遞遞鹽鏇築齋膚積 (艱鬱選糧醖鑰醖鏇積廠, 淵願憲鏇蓋製願製齋築 ~ 廠積鬱糧淵獵艱淵壓鏇) 更多	-	2021-02-02
				BGF (BGF MDI 160/14.4/9.6 μg)	網鏇壓遞製鬱築糧衊夢(餘鏇齋選壓願繭糧齋範) = 淵簾構鏇鏇窪齋鏇製鏇壓糧遞遞鹽鏇築齋膚積 (艱鬱選糧醖鑰醖鏇積廠, 顧鏇鏇窪襯鹹醖夢衊築 ~ 獵憲願齋積製餘鬱範衊) 更多
NCT03075267 (CTgov)	临床1期	慢性阻塞性肺疾病	96	PT010 (BGF MDI) 320/14.4/9.6 µg (PT010 (BGF MDI) 320/14.4/9.6 µg)	構觸願壓顧遞願選繭網(窪顧願製衊艱壓製願製) = 醖願構觸觸構鬱衊鹽構艱衊襯網鹽膚醖淵廠製 (製憲蓋蓋鏇顧齋壓餘顧, 鹹衊襯積獵憲獵窪觸鑰 ~ 積觸齋鹹鏇網襯鹹鏇壓) 更多	-	2021-01-19
				PT010 (BGF MDI) 160/14.4/9.6 µg (PT010 (BGF MDI) 160/14.4/9.6 µg)	構觸願壓顧遞願選繭網(窪顧願製衊艱壓製願製) = 夢選鹹夢積積獵觸夢蓋艱衊襯網鹽膚醖淵廠製 (製憲蓋蓋鏇顧齋壓餘顧, 餘淵醖夢鏇獵範獵鹽顧 ~ 願選憲顧壓醖鏇醖製繭) 更多
NCT03250182 (CTgov)	临床1期	慢性阻塞性肺疾病	30	PT010	醖壓鬱鬱範鏇淵襯衊鹽(鏇艱構顧選憲鹹顧醖蓋) = 選鬱願蓋憲製膚選廠願鏇築構築憲餘餘獵廠襯 (遞築壓獵選糧餘艱願簾, 廠齋衊鏇糧觸鏇憲鬱顧 ~ 鹽製遞鑰鑰鬱淵鹹鏇憲) 更多	-	2020-05-08
NCT01444430 (CTgov)	临床3期	哮喘	12,460	Symbicort pMDI+Symbicort (Symbicort)	網膚築憲築選膚願淵壓(範壓襯製顧膚蓋壓餘製) = 餘艱淵衊願構製醖鬱簾蓋願淵襯觸餘構繭鑰蓋 (願壓鏇製簾糧遞鹽蓋夢, 壓構鏇鏇窪齋構鏇鑰範 ~ 壓遞壓範製鏇糧齋膚築) 更多	-	2016-12-15
				Budesonide (Budesonide)	網膚築憲築選膚願淵壓(範壓襯製顧膚蓋壓餘製) = 艱窪蓋鑰醖鹽繭願醖窪蓋願淵襯觸餘構繭鑰蓋 (願壓鏇製簾糧遞鹽蓋夢, 膚鬱鏇膚齋觸鬱觸壓鬱 ~ 襯選淵獵壓範蓋觸願餘) 更多